

Technical Report Documentation Page

1. Report No. DOT/FAA/AM-23/30	2. Government Accession No.	3. Recipient's Catalog No.
4. Title and Subtitle Risk Framework for Cabin Transmission of Infectious Diseases		5. Report Date September 2023 (Updated December 2023)
7. Author(s) Andy Anderegg, Nadya Huleatt, Gene Lin, Ilana Lisann, Rakhee Palekar Hamid Shirazi, Alex Wu		6. Performing Organization Code
9. Performing Organization Name and Address The MITRE Corporation 7515 Colshire Dr. McLean, VA 22101		8. Performing Organization Report No. 4-5.C.1-1
12. Sponsoring Agency Name and Address Office of Aerospace Medicine Federal Aviation Administration 800 Independence Ave., S.W. Washington, DC 20591		10. Work Unit No. (TRAIS)
15. Supplementary Notes Author ORCIDs: Anderegg (0000-0003-0874-5165); Huleatt (0009-0004-1963-1993); Lin (0000-0002-8875-7782); Lisann (0000-0003-1836-1704); Palekar (0000-0001-5216-3117); Shirazi (0009-0005-0155-5520); Wu (0000-0002-5526-1318); DOI: https://doi.org/10.21949/1529622		11. Contract or Grant No.
16. Abstract The Federal Aviation Administration (FAA) has assumed leadership for developing a preparedness plan for communicable disease in air travel and identifying associated research needs. The FAA's approach to the planning effort is to use its existing Safety Risk Management (SRM) process, as documented in FAA Order 8040.4B. The FAA will then use the SRM outputs as inputs to the preparedness planning activity, thereby making the latter risk-based and data-driven. The FAA tasked the MITRE Corporation's Center for Advanced Aviation System Development to develop a risk matrix suitable for use in a safety risk assessment evaluating communicable disease transmission risk in commercial air travel, specifically focusing on the gate-to-gate travel segment. To accomplish this tasking, MITRE investigated SRM process activities as documented in FAA Order 8040.4B applicable to disease transmission; interviewed relevant stakeholders; identified categories of likelihood and severity applicable to disease transmission; and used the transmission of seasonal influenza among air travel passengers to establish historically accepted societal risk thresholds. Through this method, MITRE has provided the FAA with a decision pathway to integrate data driven SRM for communicable disease transmission and to initiate preparedness planning activities.		13. Type of Report and Period Covered Technical Presentation
17. Key Word Safety Management Systems, Aeromedical Certification, Aviation Safety Risk Management, Communicable Disease		14. Sponsoring Agency Code
19. Security Classification (of this report) Unclassified	20. Security Classification (of this page) Unclassified	21. No. of Pages 14
18. Distribution Statement Document is available to the public through the National Transportation Library: https://ntl.bts.gov/ntl		

Risk Framework for Cabin Transmission of Infectious Diseases

Risk Matrix Derived from Annual Seasonal Influenza Outbreaks

Risk acceptability rationale: seasonal influenza risks are de facto “acceptable.”

- Annual seasonal influenza outbreak is the baseline for acceptable levels of aviation disease transmission risk.
- Influenza outbreak is 32 weeks of the year with no unusual mitigation efforts other than those that have been practiced for years.

Past Seasons Estimated Influenza Disease Burden

These pages includes information about the estimated burden of influenza from past seasons, including tables of the estimated influenza disease burden (and 95% credible interval [Cr I]) by age group. Information on how these estimates are calculated can be found on CDC's web page [How CDC Estimates the Burden of Seasonal Influenza in the U.S.](#)


Table 1: Estimated Flu Disease Burden, by Season — United States, 2010-2011 through 2021-2022** Flu Seasons

Season	Symptomatic Illnesses		Medical Visits		Hospitalizations		Deaths	
	Estimate	95% U I	Estimate	95% U I	Estimate	95% U I	Estimate	95% U I
2010-2011	21,000,000	(20,000,000 – 25,000,000)	10,000,000	(9,300,000 – 12,000,000)	290,000	(270,000 – 350,000)	37,000	(32,000 – 51,000)
2011-2012	9,300,000	(8,700,000 – 12,000,000)	4,300,000	(4,000,000 – 5,600,000)	140,000	(130,000 – 190,000)	12,000	(11,000 – 23,000)
2012-2013	34,000,000	(32,000,000 – 38,000,000)	16,000,000	(15,000,000 – 18,000,000)	570,000	(530,000 – 680,000)	43,000	(37,000 – 57,000)
2013-2014	30,000,000	(28,000,000 – 33,000,000)	13,000,000	(12,000,000 – 15,000,000)	350,000	(320,000 – 390,000)	38,000	(33,000 – 50,000)
2014-2015	30,000,000	(29,000,000 – 33,000,000)	14,000,000	(13,000,000 – 16,000,000)	590,000	(540,000 – 680,000)	51,000	(44,000 – 64,000)
2015-2016	24,000,000	(20,000,000 – 33,000,000)	11,000,000	(9,000,000 – 15,000,000)	280,000	(220,000 – 480,000)	23,000	(17,000 – 35,000)
2016-2017	29,000,000	(25,000,000 – 45,000,000)	14,000,000	(11,000,000 – 23,000,000)	500,000	(380,000 – 860,000)	38,000	(29,000 – 61,000)
2017-2018	41,000,000	(35,500,000 – 53,000,000)	21,000,000	(18,000,000 – 27,000,000)	710,000	(560,000 – 1,100,000)	52,000	(3,000 – 95,500)

¹ Source: Centers For Disease Control and Prevention (CDC), <https://www.cdc.gov/flu/about/burden/past-seasons.html>, accessed Sept. 13, 2023

A simple model provides a conservative estimate of acceptable outcomes for in flight influenza transmission.

- The estimate is conservative by accounting only for passengers as a source and ignoring:
 - residual contagions from prior passengers, food, and surfaces;
 - crew members and boarding process interactions with other passengers; and
 - the jetway as a second location of encounters.
- This result provides a low precision lower bound as a trigger for the need for mitigation.



Contagious passenger population on a flight (C_p): 0.2 percent \approx one contagious flu case / 500 passengers.

- 41 million estimated seasonal influenza cases in 2017-2018 (a high-rate year)¹
- 327 million U.S. population at the time
- Proportion of the general population contagious at any given time:

$$\frac{\# \text{ of cases}}{\text{population}} = \times \frac{\# \text{ of days patient is contagious}}{\# \text{ of days of the flu season}} = 12.5\% \times \frac{8 \text{ days}}{32 \text{ weeks} \times 7 \text{ days/wk}} = 0.45\%$$

- Assumption: 50 percent of contagious individuals are well enough and willing to board²

C_p 0.23% = 50% x 0.45% (~one contagious influenza case / 500 passengers)


¹ Centers For Disease Control and Prevention (CDC), <https://www.cdc.gov/flu/about/burden/past-seasons.html> accessed Sept. 13, 2023

² N. McCarthy, "The Majority Of Americans Still Go To Work While Sick [Infographic]," *Forbes*.

<https://www.forbes.com/sites/niallmccarthy/2016/11/10/the-majority-of-americans-still-go-to-work-while-sick-infographic/> accessed Sep. 15, 2023.

Number exposed per passenger (N_e): A contagious passenger who boards exposes 15 other passengers, on average.


- The number of passengers exposed varies with the aircraft configuration.
- Every contagious passenger who boards exposes N_e passengers
 - Average aircraft carried 100 passengers, size varies
 - An average of 15% of passengers fall within 2 rows of any seat on narrow and wide body aircraft
 - These range from 25% in smaller planes to less than 10% in larger planes
 - A tighter square of 2 rows \times 2 seats (\sim 15 seats) around index case provided stronger contact tracing results³
 - 2 rows X 2 seats: 7.7% (95% confidence interval [CI] of 2.6% to 17.9%)
 - 2 rows, all seats: 1.4% (95% CI of 0.5% to 3.4%)



3 Foxwell A, Roberts L, Lokuge K, et al. Transmission of [H1N1] Influenza on International Flights, May 2009. Emerging Infectious Diseases. 2011;17(7):1188-1194. doi:10.3201/eid1707.101135.

4 percent secondary attack rate (SAR) results in 0.6 secondary infections per contagious passenger.

- Empirical secondary attack rate for influenza by proximity is 4%⁴
 - Calculated by:
 - A 5% secondary attack rate to passengers seated within the 2-rows
 - The studies found a 3% risk to passengers beyond 2-rows from the infectious individual
 - These studies concluded based on the distribution that a second factor must be involved for infections beyond 2-rows and found these may be explained by contact in the ramp, boarding, or terminal areas⁵




⁴ V. Stover Hertzberg and H. Weiss, "On the 2-Row Rule for Infectious Disease Transmission on Aircraft", *Annals of Global Health*, vol. 82, no. 5, p. 819-823, 2016. DOI: <https://doi.org/10.1016/j.aogh.2016.06.003>.

⁵ Anna C. Rafferty, et. al., "Does 2x2 airplane passenger contact tracing for infectious respiratory pathogens work? A systematic review of the evidence", Published: February 2, 2023, <https://doi.org/10.1371/journal.pone.0264294>.

Disease contraction rate (D_p): 1.38×10^{-3} percent probability a passenger will contract influenza on a flight.

- 0.23% of passengers will board with a contagious case of influenza
- Average of 100 passengers⁶
- Only 15% of the passengers will sit within 2 rows of a specific seat
- 4% chance of contracting influenza
- 1.38×10^{-3} / flight (average is 2-hours)⁶ = 6.90×10^{-4} / flight hour of becoming infected on a flight
 - 1.38×10^{-3} divided by 2



⁶ Bureau of Transportation Statistics, [2018 Traffic Data for U.S Airlines and Foreign Airlines U.S. Flights | Bureau of Transportation Statistics \(bts.gov\)](https://www.bts.gov/publications/tables/2018/2018-traffic-data-for-u-s-airlines-and-foreign-airlines-u-s-flights)

⁷ Leondaridis, Yanni. MITRE Transportation Data Platform analysis of commercial flight durations show average airborne time 102 min, $\sigma = 64$ min. ~2 hours boarding to deplaning, 2023

Proposed severity and likelihood definitions for risk are consistent with FAA Order 8040.4C.

Minimal 5	Minor 4	Major 3	Hazardous 2	Catastrophic 1
Asymptomatic or self-treated illness	Illness resulting in medical visit	Illness resulting in hospitalization	Illness resulting in a fatal case	Public health system consequences are beyond aviation

Category	Less than	Greater than or Equal to
Frequent – A	1	1×10^{-5} (1 per 100,000)
Infrequent – B	1×10^{-5} (1 per 100,000)	1×10^{-6} (1 per 1,000,000)
Extremely Infrequent – C	1×10^{-6} (1 per 1,000,000)	1×10^{-7} (1 per 10,000,000)
Remote – D	1×10^{-7} (1 per 10,000,000)	1×10^{-8} (1 per 100,000,000)
Extremely Remote – E	1×10^{-8} (1 per 100,000,000)	1×10^{-9} (1 per 1,000,000,000)
Improbable – F	1×10^{-9} (1 per 1,000,000,000)	1×10^{-10} (1 per 10,000,000,000)
Extremely Improbable – G	1×10^{-10} (1 per 10,000,000,000)	0

Medical outcomes for the secondary infection vary with the severity of the outbreak.

Severity and likelihood of medical outcomes determine the placement of risk⁸

Asymptomatic or self-treated illness (level 1)

Asymptomatic or self-care rate: 52.1%

Illness resulting in doctor's visit (level 2)

Medical visit rate: 46%

Illness resulting in hospitalization (level 3)


Case Hospitalization Ratio (CHR): 1.8% - subset of medical visits

Illness resulting in a fatal case (level 4)

Case Fatality Ratio (CFR): 0.12% - subset of hospitalizations

⁸ Centers For Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), "Estimated Flu-Related Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States — 2017–2018 Flu Season," Centers for Disease Control and Prevention, <https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu/about/burden/2017-2018.htm> (accessed Dec. 7, 2023).

Used together, these elements support a risk model of conservative estimates of the outcomes for on-board transmission of influenza.



The risk matrix captures acceptable disease transmission consequences and triggers for safety risk management.

This derived matrix combines the proposed definitions of severity and assumptions of influenza seasonal outbreak acceptability.

A low fidelity forecast for monitored contact trace disease's can be applied to the matrix to anticipate the need to actively control on-board transmission risk of future outbreaks.

Likelihood Category		Severity					
		Minimal 5	Minor 4	Major 3	Hazardous 2	Catastrophic 1	
Act	Frequent (A)	Greater than 10^{-4}	Asymptomatic or self-treated symptomatic flu	Flu-related medical visit			
		Greater than 10^{-5}			flu-related hospitalization		
Monitor	Infrequent (B)	Greater than 10^{-6}					
	Extremely Infrequent (C)	Greater than 10^{-7}				flu-related death	
	Remote (D)	Greater than 10^{-8}					
	Extremely Remote (E)	Greater than 10^{-9}					
	Improbable (F)	Greater than 10^{-10}					
	Extremely Improbable (G)	Greater than 0					

Acronyms / Abbreviations

CDC	Centers for Disease Control and Prevention
CFR	Case fatality ratio
CHR	Case hospitalization ratio
FBO	Fixed-base operator
Pax	Passenger(s)
SAR	Secondary attack rate

Notices

Disclaimer

The views, opinions and/or findings contained in this report are those of The MITRE Corporation and should not be construed as an official government position, policy, or decision, unless designated by other documentation.

Distribution

This document was prepared for authorized distribution only. It has not been approved for public release.

Copyright Notice

This is the copyright work of The MITRE Corporation and was produced for the U.S. Government under Contract Number **693KA8-22-C-00001** and is subject to Federal Aviation Administration Acquisition Management System Clause 3.5-13, Rights In Data-General, Alt. III and Alt. IV (Jan. 2009). No other use other than that granted to the U.S. Government, or to those acting on behalf of the U.S. Government, under that Clause is authorized without the express written permission of The MITRE Corporation. For further information, please contact The MITRE Corporation, Contracts Management Office, 7515 Colshire Drive, McLean, VA 22102-7539, (703) 983-6000.

©2023 The MITRE Corporation. All rights reserved.

Sponsor: Federal Aviation Administration

Department No.: P233

Project No.: 100976.10.102.1013

Outcome No.: 4

PBWP Reference: 4-5.C.1-1



Center for Advanced
Aviation System Development